OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: The Rockefeller University

9 Projects | 4 Researchers | $1,512,815 Invested

2019

The Rockefeller University

Sidney Strickland, PhD

ELISA assay for cleaved high molecular weight kininogen (HKc) as a diagnostic tool for Alzheimer’s disease (AD)

  • Funding Amount: $320,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Vascular
  • Status: Closed

2015

The Rockefeller University

Ana Pereira, MD

Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Cognitive Impairment (follow-on funding)

  • Funding Amount: $50,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2015

The Rockefeller University

Hyung Jin Ahn, PhD

Improvement of a Novel Abeta-Fibrinogen Interaction Inhibitor to Treat Vascular and Cognitive Deficits in Alzheimer's Disease

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Vascular
  • Status: Closed

2012

The Rockefeller University

Ana Pereira, MD

Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Cognitive Impairment

  • Funding Amount: $250,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Status: Closed

2010

The Rockefeller University

Sidney Strickland, PhD

Interaction between Abeta and Fibrinogen: A New Therapeutic Target for Alzheimer's Disease

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2008

The Rockefeller University

Sidney Strickland, PhD

Interaction between Abeta and Fibrinogen: A New Therapeutic Target for Alzheimer's Disease

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2006

The Rockefeller University

Sidney Strickland, PhD

Screening for PAI-1 inhibitors to increase plasmin AlphaBeta- degrading activity

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2001

The Rockefeller University

Sidney Strickland, PhD

Analysis of the Role to tPA and Plasmino(gen) in Alzheimer's Disease

  • Funding Amount: $256,480
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

1999

The Rockefeller University

John Zabriskie, MD

Is Variation in the Production of TNF - In Elderly Pre-Operative Patients Predictive of Post-Operative Cognitive Complications

  • Funding Amount: $86,335
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed